TITLE:
Phase II Study of Taxotere in Combination With Exisulind in Non-Small Cell Lung Cancer (NSCLC) Patients

CONDITION:
NSCLC

INTERVENTION:
Exisulind

SUMMARY:

      The purpose of this study is to determine if the combination of Taxotere and exisulind is an
      effective and safe treatment for patients with advanced NSCLC who have failed a prior
      platinum-containing regimen.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

        Histologically documented advanced cancer or advanced platinum-refractory non-small cell
        lung cancer. Platinum refractory defined as progressive disease during a platinum regimen
        or within 6 months following treatment.

        Negative serum pregnancy test, if fertile female. Have not taken sulindac (Clinoril) on
        regular basis for any indication for one week prior to enrollment and willing to remain
        off of sulindac for the duration of the study.

        > 18 years or of legal age. Male patients, or non-pregnant and non-lactating female
        patients either using adequate birth control (oral contraceptives or Provera), surgically
        sterile or post-menopausal.

        Willingness to remain off chronic NSAIDs (with the exception of ibuprofen, naproxen, or
        aspirin) for duration of the study. Low dose aspirin for cardiovascular prevention is
        acceptable.

        No treatment with any other chemotherapy or radiotherapy within 2 weeks prior to entering
        the study.

        Exclusion Criteria:

        Any condition or any medication which may interfere with the conduct of the study.

        Known hypersensitivity to sulindac (Clinoril) or taxanes. Use of an investigational
        medication or device within one month of initiating study therapy.
      
